Bayer Aktiengesellschaft

Bayer Healthcare Aktiengesellschaft

Merck Patent Gesellschaft MIT Beschrankter Haftung

Bayeraktiengesellschaft

Frank Mauler

Arno Friedl

Joachim Mittendorf

Michael Matzke

Jean-Marie-Viktor De Vry

Verena V&ouml;hringer

Peter Spreyer

J&uuml;rgen Franz

J&uuml;rgen Dressel

Reinhard Jork

J&ouml;rg Keldenich

Michael-Harold Rock

Siegfried Raddatz

Klaus-Helmut Mohrs

Joachim Schumacher

Joachim Schuhmacher

Klaus Urbahns

Ervin Horv&agrave;th

Arnd Voerste

Bodo Junge

Hans-Georg Heine

Klemens Lustig

Markus Heil

Dirk Denzer

Heinrich Meier

Paul Naab

Reilinde Wittka

Ervin Horv&aacute;th

Jean Marie Viktor De Vry

Ervin Horvath

Volker Hinz

Jean-Marie-Victor De Vry

Karl-Heinz Schlemmer

Christoph Seyfried

Rudolf Schohe-Loop

Adrian Tersteegen

Thomas Glaser

Gerd Bartoszyk

Jörg Keldenich

Martin Hendrix

Hartmut Greiner

Rudolf Gottschlich

Dagmar Karthaus

Helmut Prucher

Karl-August Ackermann

Andrew Barber

Maria Niewöhner, Legal Representative

Jan-Bernd Lenfers

Irene Gerlach

Özkan Yalkinoglu

Dietrich Seidel

Wolfgang Karl

David Brückner

Dietrich Scherling

Manfred Stohrer

Corinna Weinz

Swen Allerheiligen

The invention relates to new substituted imidazotriazines, processes for their preparation and their use for the production of medicaments for the treatment and/or prophylaxis of cancer and neurodegenerative disorders, in particular of Parkinson's disease and of schizophrenia.

Substituted imidazotriazines

The invention relates to novel aryl and heteroaryl sulfonates of formula (Ia) and to methods for producing them and to novel aryl and heteroaryl sulfonates of formula (I) for treating and/or preventing diseases, especially for treating pain and neurodegenerative diseases, A representing (C-C)-aryl or 5-10-membered heteroaryl, D representing (C-C)-arylene or 5-10-membered heteroarylene, Rrepresenting (C-C)-alkyl, (C-C)-alkyl, the carbon chain being interrupted by one or two heteroatoms or groups chosen from the following group: &#x2014;O&#x2014;, &#x2014;S&#x2014;, &#x2014;SO&#x2014; and &#x2014;SO&#x2014;, (C-C)-alkenyl or (C-C)-alkinyl, in formula (Ia); and Rrepresenting (C-C)-alkyl, (C-C)-alkyl, the carbon chain being interrupted by one or two heteroatoms or groups chosen from the following group: &#x2014;O&#x2014;, &#x2014;S&#x2014;,&#x2014;SO&#x2014; and &#x2014;SO&#x2014;, (C-C)-alkenyl or (C-C)-alkinyl.

Aryl and heteroaryl sulfonates

The present invention relates to chromans, to processes for their preparation and to their use in medicaments, in particular as agents for treating disorders of the central nervous system.

Benzisothiazolyl-substituted aminomethyl chromanes for treating diseases of the central nervous system

The invention relates to novel phenoxyphenyl alkanesulphonates, processes for their preparation, their use for producing medicaments for the treatment and/or prophylaxis of diseases, in particular for the treatment of states of pain and neurodegenerative disorders.

Phenoxyphenyl alkanesulphonates

The present invention relates to novel arylsulphonamides and analogues, to processes for their preparation and to their use for the prophylaxis and treatment of neurodegenerative disorders, in particular for the treatment of cerebral apoplexy, craniocerebral trauma, pain and spasticity.

Arylsulphonamides and analogues

The present invention relates to new aryl ether sulphonamides and analogues, processes for their preparation and their use for the treatment of neurodegenerative disorders, in particular for the prophylaxis and treatment of neurodegenerative disorders, in particular for the treatment of cerebral apoplexy and craniocerebral trauma.

Aryl sulfonamides and analogues thereof and their use in the treatment of neurodegenerative diseases

The present invention relates to novel amino acid esters of arylsulphonamides and analogues, to processes for their preparation and to their use for the prophylaxis and treatment of neurodegenerative disorders, in particular for the treatment of cerebral apoplexy, craniocerebral trauma, pain and spasticity.

Aryl sulphonamide amino acid esters and analogues

The present invention relates to the use of known agonists of the central cannabinoid receptor CB1 for the prophylaxis and treatment of neurodegenerative disorders, in particular for the treatment of cerebral apoplexy and craniocerebral trauma.

Use of known agonists of the central cannabinoid receptor CB1

Aryl sulphonamides and analogues

The present invention relates to new aryl ether sulphonamides and analogs, processes for their preparation and their use for the treatment of neurodegenerative disorders, in particular for the prophylaxis and treatment of neurodegenerative disorders, in particular for the treatment of cerebral apoplexy and craniocerebral trauma.

Dimethyl-substituted cyclohexane diene derivatives

The substituted 4H-pyrans are prepared by reacting either aldehydes or ylidene compounds with suitably substituted .beta.-diketones. The substituted 4H-pyrans according to the invention are suitable as active compounds in medicaments, in particular for the treatment of disorders of the central nervous system.

Substituted 4H-pyrans

The invention relates to the use of acyl-substituted aminopyrans for the production of medicaments, in particular of medicaments for the treatment of disorders of the central nervous system.

Use of acyl-substituted aminopyrans

Novel arylacetamides of the formula I ##STR1## in which Q is R.sup.4 --CH(CH.sub.2 Z)--NA--, ##STR2## R.sup.1 is Ar, cycloalkyl with 3-7 C atoms or C.sub.4 -C.sub.8 -cycloalkyl-C.sub.1 -C.sub.7 -alkyl,

Acrylacetamides

Growing community of inventors

Overath, Germany

Frank Mauler